Exchange: NASDAQ·Updated 04:11 AM EDT
News
all
press releases
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
Zacks
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
In the first part of the CIDP study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said.
Stocktwits
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's riliprubart faces rising risks after MOBILIZE.read more...
Benzinga
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline
Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline...
Yahoo! Finance: News
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish...
Yahoo! Finance: News
Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price
Wedbush raised their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an 'outperform' rating in a report on Wednesday...
MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts...
MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Dianthus Therapeutics (DNTH) to Release Earnings on Monday
Dianthus Therapeutics (NASDAQ:DNTH) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-dianthus-therapeutics-inc-stock...
MarketBeat

Advertisement|Remove ads.